A/Prof Dr Helen (Honey) Heussler MD, webinar recording 13 July 2023. (from FX Research Roundup webinar)

Dr Honey Heussler describes the scientific rationale underpinning the RECONNECT cannabidiol (CBD) FX clinical trial currently underway (2023 and 2024) in Adelaide, Brisbane, Melbourne & Sydney which is seeking to understand whether the (Zynerba) ZYGEL CBD transdermal gel product helps in some behavioural issues associated with Fragile X syndrome.

Dr Heussler outlined the working of the human endocannabinoid system, the impact of Fragile X syndrome on that system, and how cannabidiol (non-THC CBD) can provide regulation and control. Dr Heussler also outlined the operation and findings of the earlier clinical trial phases which have preceded Zynerba’s current RECONNECT study.

The RECONNECT study remains open in Australia until 31 March 2024. Individuals with a diagnosis of Fragile X syndrome and who are aged 3-22 years old and have behavioural symptoms may be eligible to participate in the study.

Dr Heussler is a Developmental and Behavioural Paediatrician with a dual qualification in Sleep Medicine. She is Medical Director of the Child Development Program at the Children’s Health Queensland Hospital and Health Service in Brisbane, and runs a Fragile X Clinic at the Queensland Children’s Hospital.

Watch the video recording of the webinar on our youtube channel: https://youtu.be/AU_3if1mLKg